Shelf life (days): 1460.0
Formulation: A solid
Formal Name: N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-carbamic acid, C,C'-di(methyl-d3) ester
Purity: ≥99% deuterated forms (d1-d6)
Formula Markup: C40H44D6N8O6
Formula Weight: 744.91168
CAS Number: 1801709-41-0
Notes: Daclatasvir-d6 is intended for use as an internal standard for the quantification of daclatasvir (Item No. 23730) by GC- or LC-MS. Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at a concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Deutsch
English
